QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
Log in
NASDAQ:BLUE

bluebird bio Competitors

$28.25
-0.43 (-1.50 %)
(As of 03/8/2021 12:00 AM ET)
Add
Compare
Today's Range
$28.19
Now: $28.25
$29.66
50-Day Range
$25.62
MA: $39.40
$50.53
52-Week Range
$24.24
Now: $28.25
$72.50
Volume1.04 million shs
Average Volume2.38 million shs
Market Capitalization$1.90 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.89

Competitors

bluebird bio (NASDAQ:BLUE) Vs. FATE, DNLI, KOD, VIR, HALO, and ADPT

Should you be buying BLUE stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to bluebird bio, including Fate Therapeutics (FATE), Denali Therapeutics (DNLI), Kodiak Sciences (KOD), Vir Biotechnology (VIR), Halozyme Therapeutics (HALO), and Adaptive Biotechnologies (ADPT).

Fate Therapeutics (NASDAQ:FATE) and bluebird bio (NASDAQ:BLUE) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.

Risk and Volatility

Fate Therapeutics has a beta of 1.88, meaning that its stock price is 88% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500.

Profitability

This table compares Fate Therapeutics and bluebird bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fate Therapeutics-810.13%-35.51%-25.40%
bluebird bio-256.84%-45.78%-35.14%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Fate Therapeutics and bluebird bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fate Therapeutics04902.69
bluebird bio013402.24

Fate Therapeutics currently has a consensus price target of $104.3750, suggesting a potential upside of 31.85%. bluebird bio has a consensus price target of $68.4667, suggesting a potential upside of 142.36%. Given bluebird bio's higher possible upside, analysts plainly believe bluebird bio is more favorable than Fate Therapeutics.

Valuation & Earnings

This table compares Fate Therapeutics and bluebird bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fate Therapeutics$10.68 million695.12$-98,150,000.00($1.44)-54.97
bluebird bio$44.67 million42.46$-789,610,000.00($14.31)-1.97

Fate Therapeutics has higher earnings, but lower revenue than bluebird bio. Fate Therapeutics is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

99.7% of Fate Therapeutics shares are held by institutional investors. Comparatively, 94.3% of bluebird bio shares are held by institutional investors. 21.4% of Fate Therapeutics shares are held by company insiders. Comparatively, 3.6% of bluebird bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Fate Therapeutics beats bluebird bio on 9 of the 14 factors compared between the two stocks.

Denali Therapeutics (NASDAQ:DNLI) and bluebird bio (NASDAQ:BLUE) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.

Risk and Volatility

Denali Therapeutics has a beta of 2, meaning that its stock price is 100% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500.

Profitability

This table compares Denali Therapeutics and bluebird bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Denali Therapeutics-968.59%-39.19%-30.71%
bluebird bio-256.84%-45.78%-35.14%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Denali Therapeutics and bluebird bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Denali Therapeutics01902.90
bluebird bio013402.24

Denali Therapeutics currently has a consensus price target of $65.1111, suggesting a potential upside of 14.98%. bluebird bio has a consensus price target of $68.4667, suggesting a potential upside of 142.36%. Given bluebird bio's higher possible upside, analysts plainly believe bluebird bio is more favorable than Denali Therapeutics.

Valuation & Earnings

This table compares Denali Therapeutics and bluebird bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Denali Therapeutics$26.68 million256.80$-197,610,000.00($2.07)-27.36
bluebird bio$44.67 million42.46$-789,610,000.00($14.31)-1.97

Denali Therapeutics has higher earnings, but lower revenue than bluebird bio. Denali Therapeutics is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

68.2% of Denali Therapeutics shares are held by institutional investors. Comparatively, 94.3% of bluebird bio shares are held by institutional investors. 19.3% of Denali Therapeutics shares are held by company insiders. Comparatively, 3.6% of bluebird bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Denali Therapeutics beats bluebird bio on 9 of the 14 factors compared between the two stocks.

Kodiak Sciences (NASDAQ:KOD) and bluebird bio (NASDAQ:BLUE) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.

Risk and Volatility

Kodiak Sciences has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500.

Insider and Institutional Ownership

82.3% of Kodiak Sciences shares are held by institutional investors. Comparatively, 94.3% of bluebird bio shares are held by institutional investors. 39.3% of Kodiak Sciences shares are held by company insiders. Comparatively, 3.6% of bluebird bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Kodiak Sciences and bluebird bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kodiak SciencesN/A-32.32%-23.86%
bluebird bio-256.84%-45.78%-35.14%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Kodiak Sciences and bluebird bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kodiak Sciences17302.18
bluebird bio013402.24

Kodiak Sciences currently has a consensus price target of $129.9091, suggesting a potential upside of 11.42%. bluebird bio has a consensus price target of $68.4667, suggesting a potential upside of 142.36%. Given bluebird bio's stronger consensus rating and higher possible upside, analysts plainly believe bluebird bio is more favorable than Kodiak Sciences.

Valuation & Earnings

This table compares Kodiak Sciences and bluebird bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kodiak SciencesN/AN/A$-47,370,000.00($1.25)-93.27
bluebird bio$44.67 million42.46$-789,610,000.00($14.31)-1.97

Kodiak Sciences has higher earnings, but lower revenue than bluebird bio. Kodiak Sciences is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Summary

bluebird bio beats Kodiak Sciences on 7 of the 13 factors compared between the two stocks.

Vir Biotechnology (NASDAQ:VIR) and bluebird bio (NASDAQ:BLUE) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Volatility and Risk

Vir Biotechnology has a beta of -0.99, meaning that its stock price is 199% less volatile than the S&P 500. Comparatively, bluebird bio has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500.

Insider & Institutional Ownership

54.5% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 94.3% of bluebird bio shares are owned by institutional investors. 37.2% of Vir Biotechnology shares are owned by company insiders. Comparatively, 3.6% of bluebird bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Vir Biotechnology and bluebird bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vir Biotechnology-339.61%-47.11%-39.44%
bluebird bio-256.84%-45.78%-35.14%

Analyst Recommendations

This is a breakdown of recent recommendations for Vir Biotechnology and bluebird bio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vir Biotechnology20502.43
bluebird bio013402.24

Vir Biotechnology currently has a consensus price target of $65.2857, suggesting a potential upside of 53.98%. bluebird bio has a consensus price target of $68.4667, suggesting a potential upside of 142.36%. Given bluebird bio's higher possible upside, analysts plainly believe bluebird bio is more favorable than Vir Biotechnology.

Earnings and Valuation

This table compares Vir Biotechnology and bluebird bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vir Biotechnology$8.09 million670.00$-174,680,000.00($5.76)-7.36
bluebird bio$44.67 million42.46$-789,610,000.00($14.31)-1.97

Vir Biotechnology has higher earnings, but lower revenue than bluebird bio. Vir Biotechnology is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Summary

bluebird bio beats Vir Biotechnology on 8 of the 14 factors compared between the two stocks.

Halozyme Therapeutics (NASDAQ:HALO) and bluebird bio (NASDAQ:BLUE) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Volatility and Risk

Halozyme Therapeutics has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500.

Insider & Institutional Ownership

98.5% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 94.3% of bluebird bio shares are owned by institutional investors. 2.6% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 3.6% of bluebird bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Halozyme Therapeutics and bluebird bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Halozyme Therapeutics10.78%24.29%4.08%
bluebird bio-256.84%-45.78%-35.14%

Analyst Recommendations

This is a breakdown of recent recommendations for Halozyme Therapeutics and bluebird bio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Halozyme Therapeutics01902.90
bluebird bio013402.24

Halozyme Therapeutics currently has a consensus price target of $42.9167, suggesting a potential upside of 8.62%. bluebird bio has a consensus price target of $68.4667, suggesting a potential upside of 142.36%. Given bluebird bio's higher possible upside, analysts plainly believe bluebird bio is more favorable than Halozyme Therapeutics.

Earnings and Valuation

This table compares Halozyme Therapeutics and bluebird bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Halozyme Therapeutics$195.99 million27.27$-72,240,000.00($0.50)-79.02
bluebird bio$44.67 million42.46$-789,610,000.00($14.31)-1.97

Halozyme Therapeutics has higher revenue and earnings than bluebird bio. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Summary

Halozyme Therapeutics beats bluebird bio on 10 of the 14 factors compared between the two stocks.

Adaptive Biotechnologies (NASDAQ:ADPT) and bluebird bio (NASDAQ:BLUE) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Volatility and Risk

Adaptive Biotechnologies has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, bluebird bio has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500.

Insider & Institutional Ownership

80.8% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 94.3% of bluebird bio shares are owned by institutional investors. 22.2% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 3.6% of bluebird bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Adaptive Biotechnologies and bluebird bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adaptive Biotechnologies-132.32%-20.15%-13.09%
bluebird bio-256.84%-45.78%-35.14%

Analyst Recommendations

This is a breakdown of recent recommendations for Adaptive Biotechnologies and bluebird bio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adaptive Biotechnologies02402.67
bluebird bio013402.24

Adaptive Biotechnologies currently has a consensus price target of $61.40, suggesting a potential upside of 61.03%. bluebird bio has a consensus price target of $68.4667, suggesting a potential upside of 142.36%. Given bluebird bio's higher possible upside, analysts plainly believe bluebird bio is more favorable than Adaptive Biotechnologies.

Earnings and Valuation

This table compares Adaptive Biotechnologies and bluebird bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adaptive Biotechnologies$85.07 million62.40$-68,610,000.00($1.01)-37.75
bluebird bio$44.67 million42.46$-789,610,000.00($14.31)-1.97

Adaptive Biotechnologies has higher revenue and earnings than bluebird bio. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Summary

Adaptive Biotechnologies beats bluebird bio on 9 of the 13 factors compared between the two stocks.


bluebird bio Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Fate Therapeutics logo
FATE
Fate Therapeutics
2.0$79.16-5.7%$7.42 billion$10.68 million-43.02
Denali Therapeutics logo
DNLI
Denali Therapeutics
1.3$56.63-7.8%$6.85 billion$26.68 million-25.62
Kodiak Sciences logo
KOD
Kodiak Sciences
1.5$116.59-3.3%$5.96 billionN/A-50.25Analyst Report
Vir Biotechnology logo
VIR
Vir Biotechnology
1.7$42.40-6.6%$5.42 billion$8.09 million-17.97Analyst Report
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$39.51-3.5%$5.34 billion$195.99 million246.94
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.6$38.13-10.8%$5.31 billion$85.07 million-40.14Analyst Revision
News Coverage
Gap Down
Twist Bioscience logo
TWST
Twist Bioscience
1.6$105.48-11.4%$5.13 billion$90.10 million-28.13
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$35.46-4.1%$4.99 billionN/A-16.65Analyst Report
Analyst Revision
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$31.57-2.5%$4.64 billionN/A-16.44Analyst Upgrade
Gap Down
China Biologic Products logo
CBPO
China Biologic Products
0.8$117.50-0.2%$4.63 billion$503.70 million32.82Upcoming Earnings
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$71.28-1.9%$4.13 billion$20,000.00-5.07Analyst Report
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$72.70-2.3%$3.56 billionN/A-41.78
Revolution Medicines logo
RVMD
Revolution Medicines
1.5$43.56-4.5%$3.20 billion$50.04 million0.00Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
RLAY
Relay Therapeutics
1.8$35.01-6.8%$3.15 billionN/A0.00
NantKwest logo
NK
NantKwest
1.1$28.28-5.2%$3.08 billion$40,000.00-39.83Decrease in Short Interest
Gap Down
Editas Medicine logo
EDIT
Editas Medicine
1.4$40.54-2.7%$2.73 billion$20.53 million-23.30Analyst Report
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$57.38-10.4%$2.56 billion$125.57 million-33.56Analyst Downgrade
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$8.79-1.0%$2.47 billion$31.43 million-6.02Analyst Revision
News Coverage
Gap Down
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$49.47-2.6%$2.20 billionN/A0.00Upcoming Earnings
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$11.10-0.5%$1.97 billion$48.83 million-14.60
AlloVir logo
ALVR
AlloVir
1.4$29.85-2.2%$1.94 billionN/A0.00
Vericel logo
VCEL
Vericel
1.5$40.75-4.3%$1.87 billion$117.85 million-4,075,000.00
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$42.11-1.1%$1.81 billionN/A0.00Upcoming Earnings
Scholar Rock logo
SRRK
Scholar Rock
1.3$53.17-0.7%$1.79 billion$20.49 million-22.06Upcoming Earnings
REGENXBIO logo
RGNX
REGENXBIO
1.8$39.28-1.7%$1.67 billion$35.23 million-15.84Analyst Report
Translate Bio logo
TBIO
Translate Bio
1.4$21.75-2.2%$1.64 billion$7.80 million-20.33Upcoming Earnings
Analyst Report
Ocugen logo
OCGN
Ocugen
1.1$8.63-1.3%$1.62 billionN/A-5.83Decrease in Short Interest
Analyst Revision
Gap Down
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$10.88-4.4%$1.56 billion$102.43 million-18.13
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$70.10-3.8%$1.56 billionN/A-47.36Analyst Report
News Coverage
Replimune Group logo
REPL
Replimune Group
1.5$32.66-8.1%$1.52 billionN/A-18.45
Immunovant logo
IMVT
Immunovant
1.8$15.39-12.2%$1.51 billionN/A-11.93High Trading Volume
Unusual Options Activity
Gap Down
Alector logo
ALEC
Alector
1.3$17.05-0.1%$1.36 billion$21.22 million-7.65
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$16.18-0.7%$1.35 billionN/A-3.50Analyst Revision
FMTX
Forma Therapeutics
1.8$30.91-9.6%$1.27 billion$100.56 million0.00Upcoming Earnings
Decrease in Short Interest
News Coverage
PCVX
Vaxcyte
1.8$24.48-2.9%$1.25 billionN/A0.00Upcoming Earnings
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.98-0.9%$1.16 billion$356.07 million7.83
Cortexyme logo
CRTX
Cortexyme
1.3$36.73-3.4%$1.09 billionN/A-15.30Gap Down
Passage Bio logo
PASG
Passage Bio
2.0$19.46-1.9%$1.05 billionN/A0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Down
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$10.55-5.4%$1.03 billion$250,000.00-8.31Analyst Downgrade
Mesoblast logo
MESO
Mesoblast
1.4$8.72-5.2%$1.02 billion$32.16 million-9.91Earnings Announcement
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.3$12.07-4.1%$979.87 millionN/A-5.64Gap Up
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$25.16-16.7%$950.07 millionN/A0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$19.42-3.5%$911.13 million$69.89 million-4.63Unusual Options Activity
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$24.84-1.0%$897.12 millionN/A-4.11
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$23.12-3.1%$881.29 millionN/A0.00News Coverage
Inhibrx logo
INBX
Inhibrx
1.7$22.17-19.0%$836.08 millionN/A0.00Upcoming Earnings
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.70-2.0%$799.10 million$42.74 million-230.00Upcoming Earnings
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$23.89-3.8%$798.45 millionN/A-9.87
Cellectis logo
CLLS
Cellectis
1.3$18.28-0.5%$776.64 million$22.99 million-9.72Earnings Announcement
Analyst Report
Gap Down
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$4.90-4.7%$760.18 million$1.12 million-4.95
This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.